去氨加压素在服用抗血小板药物患者自发性非创伤性脑出血中的应用:系统评价与贝叶斯Meta分析
该系统评价与贝叶斯Meta分析纳入7项比较去氨加压素与安慰剂/对照/常规治疗在抗血小板治疗相关脑出血患者中的研究。结果显示去氨加压素与总体死亡率(OR 1.23; 95%CrI 0.79-1.91)、院内死亡率(OR 1.41; 95%CrI 0.88-2.26)或良好功能结局(OR 0.66; 95%CrI 0.34-1.31)均无显著差异。后验分布分析提示去氨加压素组血栓栓塞并发症和神经功能不良结局比例可能增加。目前缺乏令人信服的获益证据,且存在伤害信号,不支持常规使用去氨加压素。
要点
- 在抗血小板治疗相关脑出血患者中,去氨加压素与总体死亡率无显著差异(OR 1.23; 95%CrI 0.79-1.91)。
- 去氨加压素与院内死亡率(OR 1.41; 95%CrI 0.88-2.26)和良好功能结局(OR 0.66; 95%CrI 0.34-1.31)亦无显著关联。
- 贝叶斯后验分析提示去氨加压素组血栓栓塞并发症和神经功能不良结局比例可能增加。
- 目前没有明确、有充分支持的建议对抗血小板治疗相关脑出血患者使用去氨加压素。
适用人群与场景
- 服用抗血小板药物的自发性非创伤性脑出血患者(APT-ICH)。
- 研究场景为比较去氨加压素与安慰剂/对照/常规治疗的住院患者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:系统评价与贝叶斯Meta分析,共纳入7项研究。
- 主要终点:总体死亡率无差异(OR 1.23; 95%CrI 0.79-1.91)。
- 次要终点:院内死亡率无差异(OR 1.41; 95%CrI 0.88-2.26);良好功能结局无差异(OR 0.66; 95%CrI 0.34-1.31)。
- 后验分布分析提示去氨加压素组血栓栓塞并发症和神经功能不良结局比例可能增加。
证据类型、等级与局限
- 证据类型:系统评价与贝叶斯Meta分析。
- 证据等级或推荐强度:原文未提及。
- 局限:原文未明确说明纳入研究的偏倚风险、异质性或Meta分析的具体局限;仅提及既往去氨加压素早期试验数量有限。
对床旁实践的改变
- 不支持常规对抗血小板治疗相关脑出血患者使用去氨加压素,因缺乏获益证据且存在潜在伤害信号。
- 临床决策时应警惕去氨加压素可能增加血栓栓塞并发症和神经功能不良结局的风险。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Antiplatelet therapy-associated intracerebral hemorrhage (APT-ICH) remains a significant neurological concern due to high morbidity and mortality among these patients. Early trials of desmopressin (DDAVP) suggested clinical benefit; however, the number of studies available at the time was limited. This systematic review and Bayesian meta-analysis aim to answer whether administration of DDAVP among patients with APT-ICH improves clinical course. Five databases were searched for studies comparing DDAVP and placebo/control/usual care in patients with APT-ICH. Bayesian meta-analysis was performed using a random-effects model with three different priors. A total of seven studies were included. There was no difference in overall mortality [odds ratio (OR) 1.23; 95% credible interval (CrI) 0.79-1.91], in-hospital mortality (OR 1.41; 95% CrI 0.88-2.26), or good functional outcome (OR 0.66; 95% CrI 0.34-1.31). Posterior distribution analysis suggested a possible increase in thromboembolic complications and the proportion of patients with poor neurological outcomes among patients on DDAVP. There is currently a lack of convincing evidence of benefit regarding the administration of DDAVP for patients with APT-ICH. Furthermore, there are several signals that raise concerns for harm.This review indicates that there is no clear, well-supported recommendation to administer DDAVP to patients with APT-ICH.The results of Bayesian meta-analysis reveal a concerning signal for harm with DDAVP administration.
参考来源
- Łajczak P, de Oliveira RR, Łajczak A, et al. Use of Desmopressin in Spontaneous Nontraumatic Intracerebral Hemorrhage Among Patients Taking Antiplatelet Therapy: Systematic Review and Bayesian Meta-analysis. Neurocrit Care. 2026. PMID: 42864513. doi:10.1007/s12028-026-02672-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。